| |
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
Today’s Big NewsJul 8, 2025 |
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today!
|
|
| By Gabrielle Masson Biopharma layoff rounds reported this May hit an all-time high, with 29 RIFs occurring—the most of any month reported over the last four years Fierce Biotech has spent tracking the measure. |
|
|
|
By Kevin Dunleavy Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are infected with malaria. The nod is for a new formulation of Coartem, which is also known commercially in come countries as Riamet. |
By Conor Hale The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo wristband developed by Aktiia. |
By Darren Incorvaia KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. Now, a new $20 million effort from the Chan Zuckerberg Initiative and Innovative Genomics Institute endeavors to ensure KJ’s treatment isn’t a one-off. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more.
|
|
By Fraiser Kansteiner As biosimilars struggle to live up to their promise of cutting costs and improving access to biologic medicines for U.S. patients, more than 39 advocacy groups are championing recent bipartisan efforts to cut through the bureaucracy that they believe has kept adoption at bay. |
By Andrea Park Several months after the FDA signed off on Bimzelx’s label expansion into hidradenitis suppurativa, UCB is expanding an existing campaign to include the drug’s new indication. |
By Gabrielle Masson Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s main goal. |
By Zoey Becker The airline accused more than 40 generic drugmakers of engaging in a wide-spanning price-fixing scheme that allegedly cost the company "hundreds of millions" of dollars over the years. |
By Conor Hale LumiThera's approach employs different wavelengths of low-level light to help stimulate mitochondrial activity in the cells of the retina. |
By Nick Paul Taylor Achieve Life Sciences has signed up Omnicom to support the launch of nicotine dependence treatment cytisinicline, positioning the biotech to tap into capabilities at multiple agencies to reach patients and healthcare professionals. |
By Conor Hale The series B financing comes quickly after the company’s $40 million series A, which closed this past April, and follows its presentations at the Heart Rhythm Society annual meeting. |
By James Waldron Many of Concentra’s targets are biotechs that have found themselves in tough times, and Cargo certainly fits the bill. |
By Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| |
|
